Senior clinicians overseeing cancer care in England and Wales have raised concerns that deficiencies in National Health Service (NHS) provisions are leading to a substantial number of patients not receiving recommended treatments for certain cancers.

The National Cancer Audit Collaborating Centre (NATCAN) has identified notable issues particularly affecting prostate, kidney, and colon cancers.

NATCAN, responsible for audits across nine major cancers accounting for 80% of cases, has reported significant variations in treatment across different hospitals.

These discrepancies in accessing nationally recommended therapies are potentially jeopardizing patient outcomes.

Key findings from NATCAN's data include:

- Prostate Cancer: Approximately 30% of patients diagnosed with high-risk prostate cancer do not receive curative interventions such as surgery or radiotherapy.

Treatment rates vary between 20% and 43% across different healthcare facilities.

- Colon Cancer: About 34% of patients with stage three colon cancer do not commence chemotherapy within three months post-surgery.

In certain hospitals, this figure exceeds 60%.

- Kidney Cancer: Half of the patients with stage four renal cell carcinoma, a form of kidney cancer that has metastasized, do not receive drug treatments.

Treatment rates range from 20% to 85% depending on the hospital.

While some patients may opt out of treatment or may not be medically fit for certain therapies, NATCAN indicates that these factors do not fully account for the extent of the shortfalls or the inter-hospital variations observed.

In response to these findings, both the English and Welsh governments have emphasized their commitment to enhancing cancer services.

England is currently formulating a new cancer strategy aimed at revolutionizing care delivery.

The case of Ian Pattison, diagnosed with high-risk prostate cancer in 2020 at the age of 65, underscores the impact of receiving appropriate treatment.

After undergoing the recommended combination of hormone therapy and radiotherapy, his cancer is now in remission, and he reports a good quality of life at age 70.

Professor Ajay Aggarwal, Clinical Director at NATCAN, expressed concern over the significant number of patients not receiving recommended treatments and the perplexing variations between hospitals.

He emphasized the potential for existing treatments to substantially improve patient outcomes if applied more consistently.

Factors contributing to these disparities may include assumptions about older patients' ability to tolerate treatments, staffing and capacity challenges, and smaller hospitals not referring patients to specialized centers.

Notably, even some major centers exhibit deficiencies in treatment rates for specific cancers.

Tim Mitchell, President of the Royal College of Surgeons of England, highlighted that inconsistent delivery of available world-class cancer treatments means many patients miss out, potentially leading to preventable suffering or mortality.

Cancer charities have stressed that addressing these failings is as crucial as reducing waiting times.

Eve Byrne of Macmillan Cancer Support described the findings as 'staggering' and called for prioritizing the reduction of treatment variations in the forthcoming national cancer strategy.

Concerns have also been raised about potential disparities affecting patients from deprived, rural, or ethnically diverse communities.

Amy Rylance from Prostate Cancer UK noted that patients are being denied their best chance of a cure, emphasizing the need for immediate change.

NHS England's Cancer Director, Professor Peter Johnson, acknowledged the variability in patient experiences and affirmed efforts to address these issues.

A spokesperson for the Department of Health and Social Care reiterated the commitment to ensuring equitable access to cancer care across regions and to tackling health inequalities as part of the NHS's ongoing development.

A new cancer strategy is anticipated to be published in the latter half of the year, with Health Secretary Wes Streeting indicating it will bring transformative changes to services.

The Welsh government has also stated its collaboration with the NHS to plan, deliver, recover, and enhance cancer services, acknowledging areas identified by the audit that require further attention.